Common antidepressant may ease long COVID’s crushing fatigue
A low-cost antidepressant may offer new hope for people struggling with long COVID fatigue. In a randomized clinical trial involving 399 adults, fluvoxamine significantly reduced fatigue and improved quality of life compared with a placebo, making it one of the first medications
The potential for fluvoxamine to alleviate long COVID fatigue is a significant development, particularly given the dearth of effective treatments for this condition. As a repurposed medication, fluvoxamine offers a promising solution that could be rapidly scaled up to meet the needs of a large patient population. Its low cost also makes it an attractive option for widespread use.
In the context of the ongoing COVID-19 pandemic, the need for effective treatments for long COVID symptoms has become increasingly pressing. Long COVID, also known as post-acute COVID-19 syndrome (PACS), affects millions of people worldwide, with fatigue being one of the most debilitating symptoms. The fact that fluvoxamine, an existing antidepressant, may be able to provide relief for these patients highlights the importance of continued research into the therapeutic applications of established medications.
As researchers continue to explore the potential of fluvoxamine and other treatments for long COVID, inventors and clinicians will be watching to see how these findings translate into real-world clinical practice. Key questions to watch include: How will fluvoxamine be integrated into treatment guidelines for long COVID? What are the potential side effects and interactions with other medications? And what further research is needed to fully understand the mechanisms by which fluvoxamine alleviates long COVID fatigue?
Originally reported by sciencedaily.com. InventorsNews adds analysis for science & discovery readers.